Promising therapies under investigation in AL amyloidosis: anti-fibril agents & bispecifics

Pedro Vianna, MD, Dana-Farber Cancer Institute, Boston, MA, gives an overview of promising therapies under investigation for light chain (AL) amyloidosis, including anti-fibril monoclonal antibodies and bispecific antibodies. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.